Senate’s Comparative Effectiveness Language Emphasizes Clinical Over Cost
This article was originally published in The Gray Sheet
Executive Summary
Comparative effectiveness research funding of $1.1 billion passed the House and got approval from the Senate Appropriations Committee as part of an $800 billion-plus economic stimulus package last week; but device firms and some patient and physician groups are pushing for the Senate language to win out when it comes time to reconcile the bills
You may also be interested in...
Former Medicare Officials Urge Reforms To Coverage Process
Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.
Former Medicare Officials Urge Reforms To Coverage Process
Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.
Industry Seeks Collaborative Role In HHS Comparative-Effectiveness Research
Industry leaders are urging federal agencies to keep private firms and trade associations in the loop as they make policy decisions regarding comparative-effectiveness research